Academic Progress-BIOTECH PHARMACEUTICAL CO., LTD_EGF Vaccine_ Nimotuzumab

BIOTECH

Home
About Us
About Us

BPL is a high-tech China-Cuba joint venture among first group engaged in the development, production and sales of monoclonal antibodies in China.
S&T
S&T

International-standard humanized monoclonal antibody preparation processes and large-scale, continuous mammalian cell culture technology.
- Research Areas
- Technology Platforms
Research and Development
Research and Development

China has developed nivolumab, a humanized monoclonal antibody drug (trade name: TaiXinSheng), for the treatment of malignant tumors.
Blog
Blog

Integrating industry-related media coverage as well as the company’s various activities and updates.
- Company News
- Media Reports
Join Us
Join Us

Boasting a postdoctoral research workstation and diverse career opportunities, we sincerely invite talented individuals from all fields to join Baite.
- Post-Doctoral Center
Contact Us
Contact Us

ThaiXinLife Consultation Hotline: +86 4006592330
Company Main Line: +86-10-51571020
- Contact Us

Image Name

Marketed Products

Academic Progress

First Secretary of the Central Committee of the Communist Party of Cuba and Chairman of the Republic of Cuba, Díaz, met with Bai Xianhong, Chairman of Biotech Pharma, and his delegation.

First Secretary of the Central Committee of the Communist Party of Cuba and Chairman of the Republic of Cuba, Díaz, met with Bai Xianhong, Chairman of Biotech Pharma, and his delegation.

[Shengsheng Case Study] Issue 271: Exploring Nivolumab in the Treatment of Large, Locally Advanced Cervical Cancer

[Shengsheng Case Study] Issue 271: Exploring Nivolumab in the Treatment of Large, Locally Advanced Cervical Cancer

[Shengsheng Case Study] Issue 271: Exploring Nivolumab in the Treatment of Large, Locally Advanced Cervical Cancer

Nimotuzumab ushers in a new era of pancreatic cancer treatment! Led by Professors Qin Shukai and Li Jin, the groundbreaking findings from the NOTABLE study have been featured in a top-tier international journal.

Nimotuzumab ushers in a new era of pancreatic cancer treatment! Led by Professors Qin Shukai and Li Jin, the groundbreaking findings from the NOTABLE study have been featured in a top-tier international journal.

Nimotuzumab ushers in a new era of pancreatic cancer treatment! Led by Professors Qin Shukai and Li Jin, the groundbreaking findings from the NOTABLE study have been featured in a top-tier international journal.

[Breaking News] The main paper of the NOTABLE study, led by Professors Qin Shukai and Li Jin, has been published in the prestigious international journal JCO.

[Breaking News] The main paper of the NOTABLE study, led by Professors Qin Shukai and Li Jin, has been published in the prestigious international journal JCO.

[Breaking News] The main paper of the NOTABLE study, led by Professors Qin Shukai and Li Jin, has been published in the prestigious international journal JCO.

[Case Report] Issue 270: A Case of Tongue Cancer Treated with Nilotinib Combined with Immunotherapy

[Case Report] Issue 270: A Case of Tongue Cancer Treated with Nilotinib Combined with Immunotherapy

[Case Report] Issue 270: A Case of Tongue Cancer Treated with Nilotinib Combined with Immunotherapy

[Happy Life Case] Issue 269: One Elderly Patient with Cervical Cancer Treated with Nimotuzumab

[Happy Life Case] Issue 269: One Elderly Patient with Cervical Cancer Treated with Nimotuzumab

< 1...20 21 22...88 >

Biotech pharmaceutical co., Ltd

Tel: +86-400-659-2330

Exchange Tel: +86-10-51571020

Email: cooperation@biotechplc.com

BD Dept: bd@biotechplc.com

Image Name

Address：NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176

Biotech pharmaceutical co., Ltd

互联网药品信息编号：(京)非经营性2016-0046

Powered by：CEglobal

Business License

中企跨境-全域组件 1.92 制作前进入CSS配置样式

导航下拉添加类名.active

在线客服添加返回顶部

右侧在线客服样式 1,2,3 1

图片alt标题设置： BIOTECH PHARMACEUTICAL CO., LTD

表单验证提示文本： Content cannot be empty!

循环体没有内容时： Sorry, no matching items were found.

CSS / JS 文件放置地